NCT00877838View on ClinicalTrials.gov

Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks With Aura

PHASE2UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

March 31, 2010

Study Completion Date

December 31, 2010

Conditions
Migraine With Aura
Interventions
DRUG

NXN-188

NXN-188 600 mg (3 gelatin capsules each containing 200 mg) when experiencing migraine aura.

DRUG

Placebo

Gelatin capsules resembling the ones containing the active substance

Trial Locations (1)

2600

RECRUITING

Danish Headache Center, Glostrup Municipality

Sponsors

Collaborators (1)

NeurAxon Inc.
All Listed Sponsors
collaborator

NeurAxon Inc.

INDUSTRY

lead

Danish Headache Center

OTHER